Our mission is to reshape the disease treatment paradigms by discovering and developing a precision medicine-based portfolio of novel small molecule MGDs that selectively eliminate therapeutically relevant proteins in a broad range of indications with significant unmet medical need.
There are
11 – 50
employees in the company
Offices
Headquartered in United States with additional laboratory facilities in Switzerland, Monte Rosa Therapeutics is a private company launched in 2020.